Table 2.

Dose-response study of PNU-100480 and linezolid againstM. tuberculosis ATCC 35801 in mice

Treatment group, dose (mg/kg)aLog10CFU/organ (mean ± SD)
SpleenLung
Early controls (8)b 8.06 ± 0.07c 8.17 ± 0.17
Late controls (7)6.70 ± 0.657.39 ± 0.39
Linezolid, 25 (4)5.85 ± 0.826.64 ± 0.46
Linezolid, 50 (7)6.11 ± 0.116.26 ± 0.30
Linezolid, 100 (6)5.34 ± 0.305.52 ± 0.20
PNU-100480, 25 (7)6.21 ± 0.446.96 ± 0.22
PNU-100480, 50 (7)5.40 ± 0.325.95 ± 0.64
PNU-100480, 100 (8)4.59 ± 0.314.49 ± 0.50
  • a Treatment was started 1 week after the mice received 2 × 107 viable mycobacteria.

  • b Values in parentheses are numbers of mice per group; initially, there were eight mice/group; the lower numbers are due to death presumably secondary to tuberculosis for all mice except one mouse in the group receiving linezolid at 100 mg/kg. That mouse died because of a technical error.